Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK.

Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK.
复制标题

两个 M-T 钩残基大大提高了 HIV-1 融合抑制剂 SC29EK 的抗病毒活性和耐药性

DOI:
10.1186/1742-4690-11-40
复制
发表时间:
2014-05-27
期刊:
影响因子:
3.3
通讯作者:
He Y
He Y
中科院分区:
医学2区
文献类型:
--
作者:
Chong H;Qiu Z;Sun J;Qiao Y;Li X;He Y

文献摘要

参考文献

被引文献

相似文献

背景:衍生自 HIV-1 gp41 C 端七肽重复序列 (CHR) 的肽,如 T20 (Enfuvirtide) 和 C34 是有效的病毒融合抑制剂。我们最近发现CHR肽的两个N端残基(Met115和Thr116)形成独特的M-T钩结构,可以大大增强抑制剂的结合和抗HIV活性。在这里,我们应用两个 M-T 钩残基来优化 SC29EK,这是一种具有有效抗 HIV 活性的静电约束肽抑制剂。结果:所得肽 MT-SC29EK 显示出显着增加的结合亲和力,并且可以更有效地阻断六螺旋束 (6-HB) 的形成。正如预期的那样,MT-SC29EK 有效抑制 HIV-1 进入和感染,特别是针对那些 T20 和 SC29EK 耐药的 HIV-1 变体。更重要的是,MT-SC29EK及其简写形式(MT-SC22EK)在体外选择过程中难以诱导HIV-1耐药,这表明它们对耐药性发展具有较高的遗传障碍。结论:我们的研究证实了M-T钩结构是设计新型HIV-1融合抑制剂的重要策略,并为临床开发提供了理想的候选者。
Background:Peptides derived from the C-terminal heptad repeat (CHR) of HIV-1 gp41 such as T20 (Enfuvirtide) and C34 are potent viral fusion inhibitors. We have recently found that two N-terminal residues (Met115 and Thr116) of CHR peptides form a unique M-T hook structure that can greatly enhance the binding and anti-HIV activity of inhibitors. Here, we applied two M-T hook residues to optimize SC29EK, an electrostatically constrained peptide inhibitor with a potent anti-HIV activity.Results:The resulting peptide MT-SC29EK showed a dramatically increased binding affinity and could block the six-helical bundle (6-HB) formation more efficiently. As expected, MT-SC29EK potently inhibited HIV-1 entry and infection, especially against those T20- and SC29EK-resistant HIV-1 variants. More importantly, MT-SC29EK and its short form (MT-SC22EK) suffered from the difficulty to induce HIV-1 resistance during the in vitro selection, suggesting their high genetic barriers to the development of resistance.Conclusions:Our studies have verified the M-T hook structure as a vital strategy to design novel HIV-1 fusion inhibitors and offered an ideal candidate for clinical development.
DOI: 10.1016/s0092-8674(00)80066-5
发表时间: 1999-10-01
期刊: CELL
影响因子: 64.5
作者:
Eckert, DM;Malashkevich, VN;Kim, PS
通讯作者: Kim, PS
针对恩夫韦肽耐药 HIV-1 菌株的有效 HIV 融合抑制剂
DOI: 10.1073/pnas.0807335105
发表时间: 2008-10-21
影响因子: 11.1
作者:
He, Yuxian;Cheng, Jianwei;Dai, Qiuyun
通讯作者: Dai, Qiuyun
DOI: 10.1073/pnas.95.26.15613
发表时间: 1998-12-22
影响因子: 11.1
作者:
Chan, DC;Chutkowski, CT;Kim, PS
通讯作者: Kim, PS
DOI: 10.1056/nejmoa0803152
发表时间: 2008-10-02
期刊: The New England journal of medicine
影响因子: --
作者:
Gulick RM;Lalezari J;Goodrich J;Clumeck N;DeJesus E;Horban A;Nadler J;Clotet B;Karlsson A;Wohlfeiler M;Montana JB;McHale M;Sullivan J;Ridgway C;Felstead S;Dunne MW;van der Ryst E;Mayer H;MOTIVATE Study Teams
通讯作者: MOTIVATE Study Teams
DOI: 10.1128/jvi.05331-11
发表时间: 2011-10-01
影响因子: 5.4
作者:
Eggink, Dirk;Bontjer, Ilja;Sanders, Rogier W.
通讯作者: Sanders, Rogier W.